Portal de Periódicos da CAPES

COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women

2021; American Association for the Advancement of Science; Volume: 13; Issue: 617 Linguagem: Inglês

10.1126/scitranslmed.abi8631

1946-6242

Caroline Atyeo, Elizabeth A. DeRiso, Christine Davis, Evan A. Bordt, Rose M. De Guzman, Lydia L. Shook, Lael M. Yonker, Alessio Fasano, Babatunde Akinwunmi, Douglas A. Lauffenburger, Michal A. Elovitz, Kathryn J. Gray, Andrea G. Edlow, Galit Alter,

Pregnancy and Medication Impact

Substantial immunological changes occur throughout pregnancy to render the mother immunologically tolerant to the fetus and allow fetal growth. However, additional local and systemic immunological adaptations also occur, allowing the maternal immune system to continue to protect the dyad against pathogens both during pregnancy and after birth through lactation. This fine balance of tolerance and immunity, along with physiological and hormonal changes, contributes to increased susceptibility to particular infections in pregnancy, including more severe coronavirus disease 2019 (COVID-19). Whether these changes also make pregnant women less responsive to vaccination or induce altered immune responses to vaccination remains incompletely understood. To define potential changes in vaccine response during pregnancy and lactation, we undertook deep sequencing of the humoral vaccine response in a group of pregnant and lactating women and nonpregnant age-matched controls. Vaccine-specific titers were comparable between pregnant women, lactating women, and nonpregnant controls. However, Fc receptor (FcR) binding and antibody effector functions were induced with delayed kinetics in both pregnant and lactating women compared with nonpregnant women after the first vaccine dose, which normalized after the second dose. Vaccine boosting resulted in high FcR-binding titers in breastmilk. These data suggest that pregnancy promotes resistance to generating proinflammatory antibodies and indicates that there is a critical need to follow prime-boost timelines in this vulnerable population to ensure full immunity is attained.